Startups
Ora is the world’s leading independent, full-service ophthalmic clinical research and product development firm with offices in the United States and Japan. Over the past 30 years, we helped our clients earn 39 FDA approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently and successfully bring their new products from concept to market. Ora’s pre-clinical and clinical models, unique methodologies and regulatory strategies have been refined and proven across thousands of projects both in the US and internationally. We bring together the world’s most extensive and experienced network of ophthalmic experts and R&D professionals to maximize the value of new product initiatives.
Overview
Location
United States, Massachusetts, Andover
Employees
201-500
Phone
+1 866-393-3767
Founded date
1977
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 22, 2022 | Trials of Tomorrow: The Latest Technologies Advancing Dry Eye Disease Research, Upcoming Webinar Hosted by Xtalks | The COVID-19 pandemic has accelerated innovation in telehealth, hybrid healthcare partnering in-person visits with online tools and new technologies with at-home patient data capture capabilities. TORONTO (PRWEB) September 22, 2022 The quin... |
| Aug 15, 2022 | Community is The New Network: Developing Clinical Trial Site Relationships in Ophthalmic Research, Upcoming Webinar Hosted by Xtalks | Reinventing the typical site network to become a more closely collaborative, integrated community will benefit investigators, patients, and ophthalmic innovators. TORONTO (PRWEB) August 15, 2022 While many of the foundational elements have ... |
| May 12, 2022 | Ora Leadership to be Featured in Upcoming Retinal Research Webinar hosted by Xtalks | TORONTO (PRWEB) May 12, 2022 Keith Lane, Vice President, Ora Posterior Segment; and Dr. Sally Tucker, Vice President, Ora Europe, will share insights and strategies for improving clinical study success, navigating development program hurdle... |
| Feb 26, 2021 | Mitotech and Essex Bio-Technology announce positive results of VISTA-2 Phase 3 clinical study in Dry Eye Disease | LUXEMBOURG (PRWEB) February 26, 2021 Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company, and Essex Bio-Technology, a China-based bio-pharmaceutical company, announced positive data from their VISTA-2 study (NCT04206020) –... |
| Dec 12, 2019 | electrifying vision: announcing our investment in 2c tech | ExSight Ventures (“EV”) joined a $10 million Series B financing round in 2C Tech Corporation Inc. (the “Company” or “2C Tech”), an early-stage biotechnology company. 2C Tech is developing nanoparticle technology to treat a number of retinal... |
Reviews 0
FAQ about Ora, Inc.
When was Ora, Inc. founded?
Ora, Inc. was founded in 1977.
What has the press written about Ora, Inc.?
Parsers VC has collected 6 articles mentioning Ora, Inc., among them “Trials of Tomorrow: The Latest Technologies Advancing Dry Eye Disease Research, Upcoming Webinar Hosted by Xtalks” (Sep 22, 2022) and “Community is The New Network: Developing Clinical Trial Site Relationships in Ophthalmic Research, Upcoming Webinar Hosted by Xtalks” (Aug 15, 2022).
Is Ora, Inc. still active?
Yes, Ora, Inc. is active; its latest activity on Parsers VC dates from Jan 7, 2025.